Executive record

Melanie Gloria

Chief Operating Officer at Immunovant, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:melanie-gloria-imvtVersion: public-0As of: 2026-09-30

Not yet claimed9 published Claims3 sources
  • Executive

Key Claims

Biography

Ms. Gloria has served as Chief Operating Officer since November 2024, previously serving as COO of ACELYRIN, Inc. and as SVP of Development Operations at Horizon Therapeutics. She also held roles at AbbVie and Abbott Laboratories in clinical program development.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. Current · dates not publishedChief Operating Officer · Immunovant, Inc.
  2. 2025 to end not publishedExecutive title: Chief Operating Officer · Organization not publishedIMVT DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec def 14a · Source published: Jul 22, 2026 · Retrieved: Sep 6, 2026

    Supports 2 claims
    • Professional Role: Chief Operating Officer at Immunovant, Inc. · Claim reviewed: Sep 6, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026

  2. IMVT DEF 14A executive officers

    sec filing · Source published: Jul 9, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  3. IMVT executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive function: Operations (COO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026